RE:WellRunning a business is not a linear process. You have got to reajust when external or internal factors brings change in your planning. It is true for every business.
The delay in the FDA approval of the plasminogen (read my last post) probably caused a delay in many part of the plan of Prometic (revenue and development of IVIG trial IMHO).
Also, from what I know and IMHO, partnering discussion on 4050 made it clear that they better develop the IP with analog like 4425 and 4547 in order to keep the IP on other applications. It was a big deal to partner 4050 for only one indication and not the others. It also helped that the analog showed better efficiancy for NASH or other diseases.
Ok they could have thought about that fact before, but the imput came along on a timeline. So they had to make ajustment on their planning.
This is not unique to Prometic. Every business in the world does that. And if they do, it is for the best interest of the company.